About the Company
we are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. biocardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its cardiamp™ and cardiallo™ therapies. clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. these programs are enabled by the company's helix™ transendocardial delivery systems and morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $BCDA News
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
Under the partnership, BioCardia is the exclusive biotherapeutic delivery partner for StemCardia’s cell therapy candidate through studies expected to result in FDA approval of an investigational new ...
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. CMS previously published a New ...
BioCardia spikes after Medicare coverage for cell therapy trial
BioCardia (BCDA) gains as Medicare approves reimbursement coverage for its Phase 3 CardiAMP Heart Failure II trial for cell ...
Biocardia phase III bolsters cell therapy data in heart failure
While preparing a follow-on phase III study of its Cardiamp cell therapy, Biocardia Inc. has mined positive interim data at a ...
BioCardia Reports Positive Interim Results From Phase III CardiAMP Cell Therapy Heart Failure Trial
(RTTNews) - BioCardia, Inc. (BCDA) shares are falling more than 23 percent on Monday morning, despite positive interim reports for its Phase III randomized trial of CardiAMP autologous cell therapy in ...
BioCardia Nabs Medicare Coverage for Heart Failure Cell Therapy Phase III Trial
The decision by CMS will allow Medicare-eligible patients in the study to receive coverage for CardiAMP treatment and related services.
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Bitdeer Technologies Group BTDR rose sharply during Monday’s session after the company reported preliminary ...
Crude Oil Down Over 1%; Quoin Pharmaceuticals Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the S&P 500 edging lower on Monday. The Dow traded down 0.20% to 39,007.30 while the NASDAQ fell 0.18% to 16,245.77. The S&P 500 also fell, ...
BiomX surges on merger deal with Adaptive Phage
BiomX (PHGE) stock surges over 120% after a stock-for-stock merger with Adaptive Phage Therapeutics, along with a $50M private placement. Read more here.
Kardia-2 prods Alnylam’s zilebesiran forward, hypertension back
Roche Holding AG, demonstrated significant systolic blood pressure reductions in patients with mild to moderate hypertension who were part of the Kardia-2 phase II study. A single dose of zilebesiran, ...
BioCardia, Inc.: BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
Partnership targets heart failure, the leading cause of death and a condition with limited treatment optionsBioCardia's biotherapeutic delivery system with established safety profile enables minimally ...
BioCardia receives CMS approval for CardiAMP cell therapy confirmatory phase III heart failure study
BioCardia receives CMS approval for CardiAMP cell therapy confirmatory phase III heart failure study: Sunnyvale, California Thursday, March 14, 2024, 13:00 Hrs [IST] Sunnyvale-hea ...
Loading the latest forecasts...